As of November 6, 2026, Kura Oncology, Inc. is a publicly traded company (Nasdaq: KURA); its largest reported holder is BVF Partners, with 9.99% on Schedule 13G/A of November 14, 2025, then Montanova Capital, LLC (9.7%). The largest insider holding is TROY WILSON, the chief executive and president, with 1,214,650 shares (1.4% of shares outstanding), per Form 4 of August 24, 2026 (Schedule 13G/A, November 14, 2025).
Is this your company?
About to sign with, pay or invest in Kura Oncology, Inc.? See the free Snapshot first.
Free to see. No signup.
Is Kura Oncology, Inc. a real, registered company?
- Kura Oncology Inc files with the SEC under CIK 1422143 (its SEC filings).
- Its shares are listed under the ticker KURA on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in San Diego, California, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under Kura Oncology, Inc. in our court records and SEC 8-K records (as of 2026-11-06).
- Leadership changes: the latest reported is Jennifer Fulk, Chief Financial Officer (Form 8-K filed 2026-09-08). Check you are dealing with the people now in charge.
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names BlackRock (filed 2026-10-27).
Who are Kura Oncology, Inc.'s owners and officers?
Kura Oncology, Inc.: incorporated in Delaware; business address in San Diego, California; industry Pharmaceutical Preparations (Schedule 13G/A, 2026-10-27).
Officers and directors, each with the role and the filing that names them:
- : Executive Officer, Director (Form D, 2024-02-05)
- : Executive Officer (Form D, 2024-02-05)
- : Executive Officer (Form D, 2024-02-05)
- : Executive Officer (Form D, 2024-02-05)
- : Executive Officer (Form D, 2024-02-05)
- : Director (Form D, 2024-02-05)
- : Director (Form D, 2024-02-05)
- : Director (Form D, 2024-02-05)
- : Director (Form D, 2024-02-05)
- : Director (Form D, 2024-02-05)
- : Director (Form D, 2024-02-05)
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-10-27 | Blackrock, Inc. | 8.9% |
| Schedule 13G/A, 2026-08-14 | Montanova Capital, LLC | 9.7% |
| Schedule 13G/A, 2026-05-15 | Armistice Capital, LLC | 4.23% |
| Schedule 13G, 2026-04-30 | Vanguard Capital Management | 5.01% |
| Schedule 13G/A, 2026-03-27 | The Vanguard Group | 0% |
| Schedule 13G/A, 2026-02-17 | Armistice Capital, LLC | 5.67% |
| Schedule 13G, 2026-02-09 | State Street Corporation | 5.7% |
| Schedule 13G/A, 2025-11-14 | Armistice Capital, LLC | 5.37% |
| Schedule 13G/A, 2025-11-14 | Bvf Partners L P/Il | 9.99% |
| Schedule 13G/A, 2025-08-15 | Armistice Capital, LLC | 7.14% |
| Schedule 13G/A, 2025-08-14 | Ecor1 Capital, LLC | 4.8% |
Questions about who owns Kura Oncology, Inc.
Who owns Kura Oncology, Inc.?
On this page, 5 holders' latest ownership filings report 5% or more of Kura Oncology, Inc.: Bvf Partners L P/Il (9.99%, Schedule 13G/A, filed 2025-11-14), Montanova Capital, LLC (9.7%, Schedule 13G/A, filed 2026-08-14), Blackrock, Inc. (8.9%, Schedule 13G/A, filed 2026-10-27), State Street Corporation (5.7%, Schedule 13G, filed 2026-02-09) and Vanguard Capital Management (5.01%, Schedule 13G, filed 2026-04-30).
Who are the largest shareholders of Kura Oncology, Inc.?
By the share each holder's latest filing reports, the largest holders of Kura Oncology, Inc. on this page are Bvf Partners L P/Il (9.99%), Montanova Capital, LLC (9.7%) and Blackrock, Inc. (8.9%).
When did Bvf Partners L P/Il buy into Kura Oncology, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Bvf Partners L P/Il on this page is the Schedule 13G/A, filed 2025-11-14, reporting 9.99%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 11 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Kura Oncology, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Kura Oncology, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Kura Oncology, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
19 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
| Filed | Person | Role | Change | Effective |
|---|---|---|---|---|
| Form 8-K, 2026-09-08 | Jennifer Fulk | Chief Financial Officer | appointed | 2026-09-08 |
Which insiders own Kura Oncology, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , the chief executive and president: 1,214,650 shares (1.4% of shares outstanding), 435,456 held directly and 779,194 indirectly (Form 4, 2026-08-24).
- , the chief legal officer: 187,002 shares (0.21% of shares outstanding) (Form 4, 2026-09-29).
- , a director: 149,557 shares (0.17% of shares outstanding), 10,000 held directly and 139,557 indirectly (Form 4, 2026-03-20).
- , the chief operating officer: 142,986 shares (0.16% of shares outstanding) (Form 4, 2026-09-29).
- , the senior vice president and finance: 142,928 shares (0.16% of shares outstanding), 142,428 held directly and 500 indirectly (Form 4, 2026-09-29).
Shares outstanding: 88,960,619 as of 2026-08-07, from the company's latest SEC cover page.
How much has Kura Oncology, Inc. raised?
| Filed | Sold | Offered |
|---|---|---|
| Form D, 2024-02-05 | $150M | $150M |
Keep reading
More on Kura Oncology, Inc. and the records around it.
Kura Oncology, Inc. elsewhere on the record
- 5%+ stake filings Oct 2026
- Leadership changes Sep 2026
Companies that share a holder
- EcoR1 Capital, LLC also filed stake reports on 20 other companies: Mereo BioPharma Group plc (Aug 2026), Alto Neuroscience, Inc. (Jul 2026), Fulcrum Therapeutics, Inc. (Jun 2026)
- Montanova Capital, LLC also filed stake reports on 22 other companies: Veradermics, Inc (Aug 2026), Abeona Therapeutics Inc. (Aug 2026), Fulcrum Therapeutics, Inc. (Aug 2026)
- BIOTECHNOLOGY VALUE FUND L P also filed stake reports on 55 other companies: Frazier Life Sciences Acquisition Corp. II (Oct 2026), Olema Pharmaceuticals, Inc. (Oct 2026), Foghorn Therapeutics Inc. (Oct 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/kura-oncology